Shield Therapeutics’ primary asset, Feraccru, has been approved by the FDA for the treatment of iron deficiency in patients with any underlying cause – the broadest possible label. It will be marketed in the US as Accrufer. This is upside to our previous assumptions and increases our peak sales potential to c$420m (vs c $250m previously). Successfully commercialising Feraccru/Accrufer through partners is now key to Shield realising its value. We expect Shield to out-license the US
26 Jul 2019
Shield Therapeutics - FDA approval attained, sales execution now key
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - FDA approval attained, sales execution now key
Shield Therapeutics Plc (STX:LON) | 1.3 0 (-7.0%) | Mkt Cap: 10.4m
- Published:
26 Jul 2019 -
Author:
Dr Susie Jana -
Pages:
3
Shield Therapeutics’ primary asset, Feraccru, has been approved by the FDA for the treatment of iron deficiency in patients with any underlying cause – the broadest possible label. It will be marketed in the US as Accrufer. This is upside to our previous assumptions and increases our peak sales potential to c$420m (vs c $250m previously). Successfully commercialising Feraccru/Accrufer through partners is now key to Shield realising its value. We expect Shield to out-license the US